American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients with Stage I Non-small Cell Lung Cancer

Chest

Volumn 142, Issue 6, 2012, Pages 1620-1635

  Donington, Jessica ^a   Ferguson, Mark ^b   Mazzone, Peter ^c   Handy, John ^d   Schuchert, Matthew ^e   Fernando, Hiran ^f   Loo, Billy ^g   Lanuti, Michael ^h   De Hoyos, Alberto ⁱ   Detterbeck, Frank ^j   Pennathur, Arjun ^e   Howington, John ^k   Landreneau, Rodney ^e   Silvestri, Gerard ^l  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Providence Cancer Center   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f BOSTON MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGING; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; EXERCISE TEST; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG INJURY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MORBIDITY; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PHYSICIAN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RADIATION DOSE; RADIOFREQUENCY ABLATION; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY; SUBLOBAR RESECTION; SURGEON; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR VOLUME; URINARY TRACT INFECTION;

EID: 84870602571     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0790     Document Type: Article

References (117)

1. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg. 2008;135(2):247-254.
2. Allen MS, Darling GE, Pechet TT, et al; ACOSOG Z0030 Study Group. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81(3):1013-1019.
3. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg. 2005;80(6):2051-2056. (Pubitemid 41718027)
4. Mentzer SJ, Swanson SJ. Treatment of patients with lung cancer and severe emphysema. Chest. 1999;116(suppl 6):477S-479S. (Pubitemid 30013162)
5. Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusić M. Survival analysis of untreated patients with non-small-cell lung cancer. Chest. 1994;106(6):1797-1800. (Pubitemid 24375145)
6. American College of Chest Physicians. Evidence-based guideline development process. American College of Chest Physicians website. http://www.chestnet.org/accp/guidelines/development-process. Accessed April 9, 2012.
7. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111(6):1710-1717. (Pubitemid 27260107)
8. Berry MF, Villamizar-Ortiz NR, Tong BC, et al. Pulmonary function tests do not predict pulmonary complications after thoracoscopic lobectomy. Ann Thorac Surg. 2010;89(4):1044-1051.
9. Goodney PP, Lucas FL, Stukel TA, Birkmeyer JD. Surgeon specialty and operative mortality with lung resection. Ann Surg. 2005;241(1):179-184. (Pubitemid 40041007)
10. Flores RM, Park BJ, Dycoco J, et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg. 2009;138(1):11-18.
11. Schipper PH, Diggs BS, Ungerleider RM, Welke KF. The influence of surgeon specialty on outcomes in general thoracic surgery: a national sample 1996 to 2005. Ann Thorac Surg. 2009;88(5):1566-1572.
12. Bolliger CT, Gückel C, Engel H, et al. Prediction of functional reserves after lung resection: comparison between quantitative computed tomography, scintigraphy, and anatomy. Respiration. 2002;69(6):482-489. (Pubitemid 35404289)
13. Giordano A, Calcagni ML, Meduri G, Valente S, Galli G. Perfusion lung scintigraphy for the prediction of postlobectomy residual pulmonary function. Chest. 1997;111(6):1542-1547. (Pubitemid 27260080)
14. Ali MK, Mountain CF, Ewer MS, Johnston D, Haynie TP. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma. Chest. 1980;77(3):337-342. (Pubitemid 10128924)
15. Nakahara K, Monden Y, Ohno K, Miyoshi S, Maeda H, Kawashima Y. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer. Ann Thorac Surg. 1985;39(3):260-265. (Pubitemid 15131343)
16. Brunelli A, Refai M, Salati M, Xiumé F, Sabbatini A. Predicted versus observed FEV1 and DLCO after major lung resection: a prospective evaluation at different postoperative periods. Ann Thorac Surg. 2007;83(3):1134-1139. (Pubitemid 46328840)
17. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg. 2010;139(4):976-981.
18. Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg. 2008;34(4):878-881.
19. Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136(5):1357-1363.
20. Pierce RJ, Sharpe K, Johns J, Thompson B. Pulmonary artery pressure and blood flow as predictors of outcome from lung cancer resection. Respirology. 2005;10(5):620-628. (Pubitemid 44944459)
21. Brunelli A, Varela G, Rocco G, et al. A model to predict the immediate postoperative FEV1 following major lung resections. Eur J Cardiothorac Surg. 2007;32(5):783-786. (Pubitemid 47513506)
22. Varela G, Brunelli A, Rocco G, et al. Predicted versus observed FEV1 in the immediate postoperative period after pulmonary lobectomy. Eur J Cardiothorac Surg. 2006;30(4):644-648. (Pubitemid 44332939)
23. Bolliger CT, Jordan P, Solèr M, et al. Pulmonary function and exercise capacity after lung resection. Eur Respir J. 1996;9(3):415-421. (Pubitemid 26117782)
24. Nezu K, Kushibe K, Tojo T, Takahama M, Kitamura S. Recovery and limitation of exercise capacity after lung resection for lung cancer. Chest. 1998;113(6):1511-1516. (Pubitemid 28307152)
25. Bobbio A, Chetta A, Carbognani P, et al. Changes in pulmonary function test and cardio-pulmonary exercise capacity in COPD patients after lobar pulmonary resection. Eur J Cardiothorac Surg. 2005;28(5):754-758. (Pubitemid 41539332)
26. Ferguson MK, Gaissert HA, Grab JD, Sheng S. Pulmonary complications after lung resection in the absence of chronic obstructive pulmonary disease: the predictive role of diffusing capacity. J Thorac Cardiovasc Surg. 2009;138(6):1297-1302.
27. Ferguson MK, Siddique J, Karrison T. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008;34(5):1085-1089.
28. Ferguson MK, Vigneswaran WT. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. Ann Thorac Surg. 2008;85(4):1158-1164.
29. Berrisford R, Brunelli A, Rocco G, Treasure T, Utley M; Audit and guidelines committee of the European Society of Thoracic Surgeons; European Association of Cardiothoracic Surgeons. The European Thoracic Surgery Database project: modelling the risk of in-hospital death following lung resection. Eur J Cardiothorac Surg. 2005;28(2):306-311.
30. Brunelli A, Charloux A, Bolliger CT, et al; European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009;34(1):17-41.
31. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT; American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl 3):161S-177S. (Pubitemid 47502806)
32. Brunelli A, Refai MA, Salati M, Sabbatini A, Morgan-Hughes NJ, Rocco G. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection. Eur J Cardiothorac Surg. 2006;29(4):567-570.
33. Cerfolio RJ, Bryant AS. Different diffusing capacity of the lung for carbon monoxide as predictors of respiratory morbidity. Ann Thorac Surg. 2009;88(2):405-410.
34. Brunelli A, Belardinelli R, Refai M, et al. Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection. Chest. 2009;135(5):1260-1267.
35. Pate P, Tenholder MF, Griffin JP, Eastridge CE, Weiman DS. Preoperative assessment of the high-risk patient for lung resection. Ann Thorac Surg. 1996;61(5):1494-1500. (Pubitemid 26150244)
36. Walsh GL, Morice RC, Putnam JB Jr, et al. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. Ann Thorac Surg. 1994;58(3):704-710.
37. Holden DA, Rice TW, Stelmach K, Meeker DP. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. Chest. 1992;102(6):1774-1779. (Pubitemid 23001226)
38. Ninan M, Sommers KE, Landreneau RJ, et al. Standardized exercise oximetry predicts postpneumonectomy outcome. Ann Thorac Surg. 1997;64(2):328-332.
39. Rao V, Todd TR, Kuus A, Buth KJ, Pearson FG. Exercise oximetry versus spirometry in the assessment of risk prior to lung resection. Ann Thorac Surg. 1995;60(3):603-608.
40. Singh SJ, Morgan MD, Hardman AE, Rowe C, Bardsley PA. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J. 1994;7(11):2016-2020. (Pubitemid 24366294)
41. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009;34(1):17-41.
42. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3(2):125-129. (Pubitemid 351323185)
43. Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061-1066. (Pubitemid 34984621)
44. Handy JR Jr, Asaph JW, Skokan L, et al. What happens to patients undergoing lung cancer surgery? Outcomes and qual ity of life before and after surgery. Chest. 2002;122(1):21-30. (Pubitemid 34754138)
45. Schulte T, Schniewind B, Dohrmann P, Küchler T, Kurdow R. The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer. Chest. 2009;135(2):322-329.
46. van der Voort van Zyp NC, Prévost JB, van der Holt B, et al. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2010;77(1):31-37.
47. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621-628.
48. Jensik RJ, Faber LP, Milloy FJ, Monson DO. Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg. 1973;66(4):563-572.
49. Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983;86(5):654-658. (Pubitemid 14228787)
50. Keenan RJ, Landreneau RJ, Maley RH Jr, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg. 2004;78(1):228-233. (Pubitemid 38833937)
51. Harada H, Okada M, Sakamoto T, Matsuoka H, Tsubota N. Functional advantage after radical segmentectomy versus lobectomy for lung cancer. Ann Thorac Surg. 2005;80(6):2041-2045. (Pubitemid 41718025)
52. Ginsberg RJ, Rubinstein LV;Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60(3):615-622.
53. Landreneau RJ, Sugarbaker DJ, Mack MJ, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113(4):691-698.
54. Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132(4):769-775. (Pubitemid 44415874)
55. Bando T, Yamagihara K, Ohtake Y, et al. A new method of segmental resection for primary lung cancer: intermediate results. Eur J Cardiothorac Surg. 2002;21(5):894-899. (Pubitemid 34308951)
56. Kondo D, Yamada K, Kitayama Y, Hoshi S. Peripheral lung adenocarcinomas: 10 mm or less in diameter. Ann Thorac Surg. 2003;76(2):350-355. (Pubitemid 36960567)
57. Schuchert MJ, Pettiford BL, Keeley S, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84(3):926-932.
58. Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg. 2003;125(4):924-928. (Pubitemid 36457515)
59. Martin-Ucar AE, Nakas A, Pilling JE, West KJ, Waller DA. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg. 2005;27(4):675-679. (Pubitemid 40409746)
60. Osaki T, Shirakusa T, Kodate M, Nakanishi R, Mitsudomi T, Ueda H. Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg. 1994;57(1):188-192.
61. Naunheim KS, Kesler KA, D'Orazio SA, Fiore AC, Judd DR. Lung cancer surgery in the octogenarian. Eur J Cardiothorac Surg. 1994;8(9):453-456.
62. Mery CM, Pappas AN, Bueno R, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest. 2005;128(1):237-245. (Pubitemid 40994479)
63. Kilic A, Schuchert MJ, Pettiford BL, et al. Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly. Ann Thorac Surg. 2009;87(6):1662-1666.
64. Iwasaki A, Hamanaka W, Hamada T, et al. Comparison between a case-matched analysis of left upper lobe trisegmentectomy and left upper lobectomy for small size lung cancer located in the upper division. Thorac Cardiovasc Surg. 2007;55(7):454-457. (Pubitemid 350013801)
65. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129(1):87-93. (Pubitemid 40038100)
66. Fernando HC, Santos RS, Benfield JR, et al. Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;129(2):261-267. (Pubitemid 40169547)
67. Altorki NK, Pass HI, Miller DL, Kernstine KH. Phase III randomised study of lobectomy versus sublobar resection in patients with small peripheral stage IA non-small cell lung cancer. CALGB-140503. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00499330.
68. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol. 2007;14(8):2400-2405. (Pubitemid 47174921)
69. Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg. 2009;8(3):364-372.
70. Sawabata N, Ohta M, Matsumura A, et al Thoracic Surgery Study Group of Osaka University. Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study. Ann Thorac Surg. 2004;77(2):415-420. (Pubitemid 38186481)
71. Birdas TJ, Koehler RP, Colonias A, et al. Sublobar resection with brachytherapy versus lobectomy for stage Ib nonsmall cell lung cancer. Ann Thorac Surg. 2006;81(2):434-438.
72. Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg. 2003;75(1):237-242. (Pubitemid 36104213)
73. Santos R, Colonias A, Parda D, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134(4):691-697. (Pubitemid 37411977)
74. Fernando HC. Surgery with or without internal radiation therapy in treating patients with stage I non-small cell lung cancer. ACOSOG Z4032. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00107172.
75. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg. 2011;142(5):1143-1151.
76. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial. J Thorac Cardiovasc Surg. 2011;142(3):554-562.
77. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest. 2002;121(4):1155-1158. (Pubitemid 34280436)
78. Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest. 2005;128(3):1461-1467. (Pubitemid 41324433)
79. Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41(1):1-11. (Pubitemid 36765477)
80. Campeau MP, Herschtal A, Wheeler G, et al. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1371-1375.
81. Chen M, Hayman JA, Ten Haken RK, Tatro D, Fernando S, Kong FM. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys. 2006;64(1):120-126. (Pubitemid 41831218)
82. Fang LC, Komaki R, Allen P, Guerrero T, Mohan R, Cox JD. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(1):108-116. (Pubitemid 44175656)
83. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45(7):787-795. (Pubitemid 44423123)
84. Collins BT, Erickson K, Reichner CA, et al. Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol. 2007;2:39.
85. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677-682.
86. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85(3):429-434. (Pubitemid 350213143)
87. Le QT, Loo BW, Ho A, et al. Results of a phase I doseescalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1(8):802-809. (Pubitemid 47181385)
88. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010-1015. (Pubitemid 41505277)
89. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 suppl 3):S94-S100. (Pubitemid 47183602)
90. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2010;68(1):72-77.
91. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):117-125. (Pubitemid 44175645)
92. Yoon SM, Choi EK, Lee SW, et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors. Acta Oncol. 2006;45(8):1108-1114. (Pubitemid 44808498)
93. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with ste reotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290- 3296.
94. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-1076.
95. Timmerman RD. Stereotactic body radiotherapy in treating patients with inoperable stage I or stage II non-small cell lung cancer. RTOG 0236. ClinicalTrials.gov. Bethesda, MD. http://clinicaltrials.gov/ct2/show/ NCT00087438.
96. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol. 2010;95(1):32-40.
97. Timmerman R. Stereotactic body radiation therapy in treating patients with stage I non-small cell lung cancer. RTOG 0618. ClinicalTrials.gov. Bethesda, MD. http://clinicaltrials.gov/ct2/show/NCT00551369.
98. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833-4839. (Pubitemid 46630909)
99. Fernando H. Surgery with or without internal radiation therapy compared with stereotactic body radiation therapy in treating patients with high-risk stage I non-small cell lung cancer. NCT01336894. ClinicalTrials.gov. Bethesda, MD. http://clinicaltrials.gov/ct2/show/NCT01336894.
100. Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology. 2010;254(1):301-307.
101. Grieco CA, Simon CJ, Mayo-Smith WW, DiPetrillo TA, Ready NE, Dupuy DE. Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol. 2006;17(7):1117-1124. (Pubitemid 44318693)
102. Hsie M, Morbidini-Gaffney S, Kohman LJ, Dexter E, Scalzetti EM, Bogart JA. Definitive treatment of poor-risk patients with stage I lung cancer: a single institution experience. J Thorac Oncol. 2009;4(1):69-73.
103. Lanuti M, Sharma A, Digumarthy SR, et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009; 137(1):160-166.
104. Lee JM, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology. 2004;230(1): 125-134. (Pubitemid 37549793)
105. Pennathur A, Luketich JD, Abbas G, et al. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg. 2007; 134(4):857-864. (Pubitemid 47454625)
106. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243(1):268-275. (Pubitemid 46579719)
107. Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg. 2005;129(3):639-644. (Pubitemid 40311325)
108. Gómez FM, Palussière J, Santos E, et al. Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed. Clin Transl Oncol. 2009;11(1):28-34.
109. Belfiore G, Moggio G, Tedeschi E, et al. CT-guided radiofrequency ablation: a potential complementary therapy for patients with unresectable primary lung cancer - a preliminary report of 33 patients. AJR Am J Roentgenol. 2004;183(4):1003-1011. (Pubitemid 44185086)
110. Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest. 2006;129(3):738-745.
111. Hiraki T, Gobara H, Iishi T, et al. Percutaneous radiofrequency ablation for clinical stage I non-small cell lung cancer: results in 20 nonsurgical candidates. J Thorac Cardiovasc Surg. 2007;134(5):1306-1312. (Pubitemid 47633617)
112. Chan VO, McDermott S, Malone DE, Dodd JD. Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques. J Thorac Imaging. 2011;26(1):18-26.
113. Zhu JC, Yan TD, Glenn D, Morris DL. Radiofrequency ablation of lung tumors: feasibility and safety. Ann Thorac Surg. 2009;87(4):1023-1028.
114. Dupuy D. Radiofrequency ablation in treating patients with stage I non-small cell lung cancer. ACOSOG Z4033. ClinicalTrials.gov. Bethesda, MD. http://clinicaltrials.gov/ct2/show/NCT00109876.
115. Yoo DC, Hillman S. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: does early post treatment positron emission tomography predict treatment outcome. Am J Roentgenol. 2011;197(2):334-340.
116. de Baère T, Palussière J, Aupérin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587-596.
117. Sano Y, Kanazawa S, Gobara H, et al. Feasibility of percutaneous radiofrequency ablation for intrathoracic malignancies: a large single-center experience. Cancer. 2007;109(7):1397-1405. (Pubitemid 46466568)